Legend Biotech Corporation
LEGN
株式のランク
#4472
Legend Biotech Corporation, through its subsidiaries, operates as a... Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
株価
$18.66
時価総額
$3.45B
変化（1日）
0.98%
変化（1年）
-41.61%
国
US
取引 Legend Biotech Corporation (LEGN)
カテゴリー
Healthcare
Legend Biotech Corporation（LEGN）のEPS
June 2026 時点のEPS TTM: $-0.50
Legend Biotech Corporationの最新の財務報告と株価によると、同社の現在のEPS（TTM）は$-0.50です。2023年末には、EPSは$-5.88で、2022年のEPS$-5.62と増加でした。
Legend Biotech CorporationのEPS履歴（2017から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $-0.50 | -74.23% |
| 2024 | $-1.94 | -67.01% |
| 2023 | $-5.88 | 4.63% |
| 2022 | $-5.62 | 2.55% |
| 2021 | $-5.48 | 6.61% |
| 2020 | $-5.14 | 154.46% |
| 2019 | $-2.02 | 3,533.09% |
| 2018 | $-0.06 | -139.71% |
| 2017 | $0.14 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | -3,564.00% |
US
|
|
| $-7.98 | 1,496.00% |
US
|
|
| $-5.29 | 958.00% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -5,648.00% |
NL
|
